The Action has not only catalyzed research in this area by bringing together almost 300 participants from across Europe and beyond, but it also catalyzed the careers of younger researchers and launched a Horizon 2020 project: COVIRNA.
COST Actions often create a platform for further collaboration and Catalysing transcriptomics research in cardiovascular disease (CardioRNA) is a prim..
The Luxembourg Institute of Health, a pioneer in translational medicine and digital health and venture capital investment firm Expon Capital, both based in Luxembourg city, have entered into a collaboration aiming to identify possible opportunities and synergies in the field of scientific research and technological development in the digital health sector. Click to read more.
Scientists at the Department of Cancer Research (DoCR) at the Luxembourg Institute of Health (LIH) have revealed the ground-breaking therapeutic potential of the compound FL3 in inhibiting oncogene translation and rewiring cancer cell metabolism, offering new hope for patients with chronic lymphocytic leukaemia (CLL), a prevalent form of cancer characterised by the overproduction and accumulation of dysfunctional B lymphocytes in various parts of the body. Click to read more.